Competing interests: A.S.K. received research funding from AstraZeneca and BeiGene, and has consulted for Abbvie, and BMS, and Galapagos, and has performed speaking engagements for AstraZeneca, BeiGene, and Eli-Lilly. J.N.A. received research funding from BeiGene, Celgene/BMS, Genentech, and Janssen, has consulted for Abbvie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Genentech, Janssen, Lilly, Merck, NeoGenomics, and Pharmacyclics. S.A.B. received research funding from AstraZeneca and BeiGene and has consulted for AbbVie, AstraZeneca, Pharmacyclics, Janssen and BeiGene. D.A.B. received research funding from Accutar, Nurix Therapeutics, Kite/Gilead, Astra Zeneca, Novartis, Incyte, and GenMab and consulting with ADC Therapeutics, Novartis, Nurix Therapeutics, and Kite/Gilead. D.B. received research funding from AbbVie, ArQule/Merck, AstraZeneca/Acerta, BeiGene, Catapult, DTRM, Genentech, Juno/Celgene/BMS, NeWave, Nurix, Pharmacyclics, TG Therapeutics, and consulted for AbbVie, BeiGene, Pharmacyclics. E.A.C received research funding from AstraZeneca, AbbVie, Nurix, Genentech/Roche, CARGO, and Genmab, and has consulted for AstraZeneca and BeiGene. M.S.D. received research funding from Ascentage Pharma, MEI Pharma, and Novartis, and has consulted for AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, Mingsight Pharmaceuticals, Secura Bio, TG Therapeutics, and Takeda. W.D. received research funding from AstraZeneca, Abbvie, BeiGene, DTRM and Merck, has consulted for Merck, BeiGene, MEI pharma, Alexion, has received honoraria from Merck, BeiGene, MEI pharma, Alexion, Octapharma, and serves on the membership on an entity’s Board of Directors for Octapharma. M.R.D. has received honoraria from Novartis, Kite/Gilead, and royalties from Abbvie. P.I. has consulted for Abbvie, AstraZeneca, DAVA Oncology, and MJH Life Sciences, served on an advisory board for BeiGene, and received honoraria from Targeted Oncology and VJ HemeOnc. M.J.M. received research funding from J&J, Genentech, Roche and Pfizer, and has consulted for Abbvie, Genentech, Novartis, Roche and Pfizer, and has served on a board/advisory committee for Abbvie, Allogene, Genmab, Genentech and Merck. S.A.P. received research funding from Janssen, AstraZeneca, Merck, and Genentech for clinical trials – all to the institution, Honoraria for participation in consulting activities/advisory board meetings for Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, Amgen, MingSight Pharmaceuticals, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie – all to the institution. L.E.R. has received research funding (paid to the institution) from Adaptive Biotechnologies, AstraZeneca, Genentech, AbbVie, Pfizer, Loxo Oncology, Aptose Biosciences, Dren Bio, and Qilu Puget Sound Biotherapeutics, has consulted for AbbVie, Ascentage, AstraZeneca, BeiGene, Janssen, Loxo Oncology, Pharmacyclics, Pfizer, TG Therapeutics, is a member of a data safety monitoring committee (DSMC) for Ascentage, served as a CME speaker for DAVA, Curio, Medscape, and PeerView, holds minority ownership interest in Abbott Laboratories, and received travel support from LOXO oncology. J.M.R. has received research funding from Abbvie, Acerta, BeiGene, Epizyme, Janssen, Loxo Oncology, Oncternal, Pharmacyclics, Velosbios and has consulted for Abbvie, AstraZeneca, ADC Therapeutics, BeiGene, BMS, Epizyme, Genentech, GenMab, Loxo Oncology, Janssen, Morphosys, Pharmacyclics, Pfizer. K.A.R. receives research funding from Genentech, AbbVie, Novartis, AstraZeneca, and LOXO@Lilly and consults for AbbVie, Genentech, AstraZeneca, Pharmacyclics, Janssen, BeiGene, LOXO@Lilly, and Alpine Immune Science. H.S. received honoraria and travel funding from Kite/Gilead. M.S. has received Research/grant support from Mustang Bio, Merck, Genentech, AbbVie, BeiGene, AstraZeneca, Genmab, Morphosys/Incyte, Vincerx, has consulted for Abbvie, Genentech, AstraZeneca, Genmab, Janssen, BeiGene, Bristol Myers Squibb, Kite Pharma, Eli Lilly, Nurix, served on Scientific advisory board for Fate Therapeutics, served on Steering committee for AstraZeneca, BeiGene; Janssen, and has stock options in Koi Biotherapeutics. G.S. has performed consulting/honoraria/speakers bureau for both Kite Pharma and BeiGene. A.S. has received consultation and/or speakers’ bureau honoraria from Abbvie, Alexion, AstraZeneca, ADC Therapeutics, BeiGene, Bristol-Myers-Squibb, Celgene, Epizyme, Genentech, Jazz Pharmaceuticals, Janssen, Kite Pharma, Lilly, Pharmacyclics, GenMab, Seagen and TG Therapeutics. D.M.S. received research funding from Abbvie, AstraZeneca, BeiGene, Genentech, Merck, and Novartis and has consulted for Abbvie, AstraZeneca, BeiGene, Genentech, Janssen, Lilly, and Pharmacyclics. S.S. has received research funding from BeiGene, Celgene/BMS, Incyte, Janssen, ADC Therapeutics, Shrodinger, Merck, Profound Bio, Gilead, has participated in advisory board/consulted for Genentech, Janssen, BeiGene, ADC, and has served as an expert witness for Abbvie. M.C.T. has received research funding (paid to the institution) from AstraZeneca, AbbVie, BeiGene, Genmab, Nurix Therapeutics, Genentech, has consulted for AstraZeneca, LOXO@Lilly, Pharmacyclics LLC, Janssen, AbbVie, BeiGene, received Honoraria from PeerView Institute for Medical Education, DAVA Oncology, Mashup Media LLC, Clinical Care Options, eScientiq, and has reimbursed travel from Nurix Therapeutics, Genmab, DAVA Oncology. P.T. has consulted for or received honoraria from AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Genentech, Genmab, Janssen, Lilly, Merck. Speaker fees: AbbVie, Adaptive Biotechnologies, AstraZeneca, Janssen, Merck, and travel support from Roche, Genmab, Merck. Y.W. receives institutional research funding from Incyte, InnoCare, LOXO Oncology, Eli Lilly, MorphoSys, Novartis, Genentech, Genmab, AbbVie, BeiGene, Merck, has served on an advisory board (compensation to institution) from Eli Lilly, LOXO Oncology, TG Therapeutics, Incyte, InnoCare, Kite, Jansen, BeiGene, AstraZeneca, Genmab, AbbVie, and has consulted (compensation to institution) for InnoCare, AbbVie, and received honorarium (to institution) from Kite. J.A.W. receives research funding from Abbvie, BeiGene, Janssen, Loxo/Lilly, Merck, and Schrodinger, and has consulted for Abbvie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo/Lilly, Merck, NeWave, and Pharmacyclics. All other authors have no competing financial interests.